Breaking News Instant updates and real-time market news.

TEVA

Teva

$20.40

0.03 (0.15%)

11:11
05/15/18
05/15
11:11
05/15/18
11:11

Teva reports publication of Phase III HALO study data in JAMA

Teva announced the publication of data from the Phase III HALO study evaluating the efficacy, safety, and tolerability of both quarterly and monthly subcutaneous dosing regimens of fremanezumab for the prevention of episodic migraine. These pivotal data were published online by The Journal of the American Medical Association. The study evaluated the use of both quarterly and monthly dosing regimens of subcutaneous fremanezumab, compared with placebo in patients with EM who had previously failed multiple medication classes. The HALO EM trial met its primary endpoint demonstrating that fremanezumab significantly reduced monthly migraine days for both quarterly and monthly dosing regimens: The baseline mean number of monthly migraine days was 8.9, 9.2, and 9.1 days in the monthly dosing, quarterly dosing, and placebo groups, respectively. During the 12-week period after the first dose, fremanezumab treatment significantly reduced monthly migraine days to 4.6 days for monthly and 4.9 days for quarterly dosing compared with 5.9 days for placebo. Response rates of greater than or equal to 50% reduction in monthly average number of migraine days were also significantly greater in monthly and quarterly dosing compared with placebo. Additionally, the baseline mean number of monthly days of any acute headache medication use was 7.7, 7.9, and 7.7 days in the monthly, quarterly, and placebo groups, respectively. Fremanezumab significantly reduced monthly days of any acute headache medication use to 4.5 days for monthly and 4.6 days for quarterly dosing compared with 5.4 days for placebo. The multicenter, randomized, double-blind, placebo-controlled, parallel-group study enrolled 875 patients and consisted of a screening visit, 28-day pre-treatment period, 12-week treatment period, and final evaluation at week 12. The most common adverse events in patients treated with fremanezumab were injection site pain, induration, and erythema.

  • 15

    May

  • 18

    May

  • 05

    Jun

  • 16

    Jun

TEVA Teva
$20.40

0.03 (0.15%)

04/27/18
JEFF
04/27/18
NO CHANGE
Target $105
JEFF
Buy
Neurocrine's Ingrezza can beat Q1 estimates, says Jefferies
Jefferies analyst Biren Amin says his firm's fifth proprietary survey on tardive dyskinesia reaffirms that Neurocrine Biosciences' (NBIX) Ingrezza is leading Teva's (TEVA) Austedo in market share for both moderate-severe and mild cases. The analyst thinks Ingrezza can modestly beat consensus estimates for Q1. He keeps a Buy rating on Neurocrine shares with a $105 price target.
04/30/18
DBAB
04/30/18
NO CHANGE
Target $22
DBAB
Buy
Deutsche raises Valeant price target on extended Xifaxan exclusivity
The stay in the Xifaxan litigation between Valeant Pharmaceuticals (VRX) and Teva (TEVA) was recently extended to July 30, 2018 from April 30, 2018, and may be extended further, Deutsche Bank analyst Gregg Gilbert tells investors in an intraday research note. According to the court docket, the companies agreed to extend the stay "because the facts and circumstances that warranted a stay as of May 15, 2017 have not materially changed," Gilbert adds. He previously modeled Xifaxan exclusivity through 2024, but pushed that out one more year saying Teva "does not yet appear to have clarity on the path forward for its generic filing." The exclusivity extension to 2025 on Valeant's largest product pushes the analyst's price target for the shares to $22 from $20. The stock in midday trading is up 19c to $18.26. Gilbert looks forward to an update from Teva when the company reports on May 3 and continues to like the risk/reward for Valeant. He keeps a Buy rating on the shares.
05/03/18
WELS
05/03/18
NO CHANGE
Target $16.5
WELS
Underperform
Teva Q1 'just what investors wanted,' says Wells Fargo
Wells Fargo analyst David Maris believes this quarter is exactly the quarter investors wanted out of Teva, namely progress on the cost cutting and raised guidance on the back of a business that is still facing a significant decline given a tough U.S. generics environment and generic Copaxone pressures. The analyst reiterates an Underperform rating and $16.50 price target on the shares.
05/07/18
FBCO
05/07/18
NO CHANGE
Target $23
FBCO
Outperform
Teva turnaround story appears generally on track, says Credit Suisse
Credit Suisse analyst Vamil Divan believes Teva's Q1 earnings were "solid" and sees his bullish thesis on the company as being on track. The analyst notes that the company's restructuring program is proceeding in line with its prior guidance and his expectations, if even a bit ahead of schedule. Divan reiterates an Outperform rating and $23 price target on the shares.

TODAY'S FREE FLY STORIES

INGIY

Ingenico

$0.00

(0.00%)

20:59
09/18/18
09/18
20:59
09/18/18
20:59
Upgrade
Ingenico rating change  »

Ingenico upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

MSFT

Microsoft

$113.24

1.05 (0.94%)

20:52
09/18/18
09/18
20:52
09/18/18
20:52
Hot Stocks
Microsoft announces new AI and mixed reality business applications for Dynamics »

In its official blog,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 28

    Oct

  • 03

    Mar

BWA

BorgWarner

$42.99

-1.17 (-2.65%)

19:34
09/18/18
09/18
19:34
09/18/18
19:34
Hot Stocks
BorgWarner sees operating margins in low-13% by FY23 vs 12.4% in FY17 »

As part of its Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 25

    Oct

JLL

Jones Lang LaSalle

$144.15

0.795 (0.55%)

19:31
09/18/18
09/18
19:31
09/18/18
19:31
Hot Stocks
Jones Lang LaSalle CFO Christie Kelly resigns »

Jones Lang LaSalle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

RACE

Ferrari

$138.31

5.465 (4.11%)

19:24
09/18/18
09/18
19:24
09/18/18
19:24
Earnings
Ferrari sees FY18 revenue over EUR3.4B »

As part of its Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

SMRT

Stein Mart

$1.97

-0.09 (-4.37%)

, INAP

Internap

$12.39

-0.33 (-2.59%)

19:02
09/18/18
09/18
19:02
09/18/18
19:02
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: Stein Mart (SMRT)…

SMRT

Stein Mart

$1.97

-0.09 (-4.37%)

INAP

Internap

$12.39

-0.33 (-2.59%)

TRVG

Trivago

$5.13

0.26 (5.34%)

PRQR

ProQR Therapeutics

$20.25

-1.4 (-6.47%)

MSFT

Microsoft

$113.24

1.05 (0.94%)

EVOP

EVO Payments

$26.27

-0.42 (-1.57%)

TSM

TSMC

$43.57

-0.2 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 28

    Oct

  • 12

    Nov

  • 15

    Nov

  • 03

    Mar

  • 21

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$290.96

1.55 (0.54%)

18:58
09/18/18
09/18
18:58
09/18/18
18:58
Periodicals
China to place new tariffs on $60B in U.S. exports, WSJ says »

China's government…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$290.96

1.55 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SQ

Square

$87.97

1.1 (1.27%)

18:55
09/18/18
09/18
18:55
09/18/18
18:55
Periodicals
Square seeks to bring 'omnichannel' experience to restaurants, CNBC says »

Square CFO Sarah Friar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

  • 20

    Sep

  • 26

    Sep

MSFT

Microsoft

$113.24

1.05 (0.94%)

18:48
09/18/18
09/18
18:48
09/18/18
18:48
Hot Stocks
Microsoft confirms raised quarterly dividend payment to 46c from 42c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 28

    Oct

  • 03

    Mar

KL

Kirkland Lake Gold

$17.57

-0.64 (-3.51%)

18:39
09/18/18
09/18
18:39
09/18/18
18:39
Hot Stocks
Kirkland Lake Gold acquires shares of Osisko Mining »

Kirkland Lake Gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

MSFT

Microsoft

$113.24

1.05 (0.94%)

18:39
09/18/18
09/18
18:39
09/18/18
18:39
Hot Stocks
Breaking Hot Stocks news story on Microsoft »

Microsoft raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 28

    Oct

  • 03

    Mar

OMAB

OMA Airports

$56.18

2.13 (3.94%)

18:23
09/18/18
09/18
18:23
09/18/18
18:23
Downgrade
OMA Airports rating change at Santander »

OMA Airports downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$113.41

-0.03 (-0.03%)

18:01
09/18/18
09/18
18:01
09/18/18
18:01
Hot Stocks
Celanese raises prices for acetate tow in Eastern Europ and Asia by $1/kg »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$132.97

0.56 (0.42%)

17:58
09/18/18
09/18
17:58
09/18/18
17:58
Periodicals
Wynn sued over allegations of rigging Boston casino bid, Bloomberg says »

Wynn Resorts and former…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$113.43

-0.18 (-0.16%)

17:48
09/18/18
09/18
17:48
09/18/18
17:48
Hot Stocks
SPDR Gold Trust holdings fall to 742.23MT from 742.53MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAZZ

Jazz Pharmaceuticals

$161.89

0.92 (0.57%)

17:35
09/18/18
09/18
17:35
09/18/18
17:35
Recommendations
Jazz Pharmaceuticals analyst commentary at BMO Capital »

Jazz Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 27

    Oct

  • 27

    Nov

  • 20

    Dec

RIG

Transocean

$11.93

0.335 (2.89%)

17:29
09/18/18
09/18
17:29
09/18/18
17:29
Initiation
Transocean initiated at Morgan Stanley »

Transocean initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NE

Noble Corp.

$6.15

0.19 (3.19%)

17:26
09/18/18
09/18
17:26
09/18/18
17:26
Initiation
Noble Corp. initiated at Morgan Stanley »

Noble Corp. initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

CCOEY

Capcom

17:24
09/18/18
09/18
17:24
09/18/18
17:24
Periodicals
Capcom shutting down Vancouver studio, Kotaku says »

Capcom Vancouver,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$77.70

0.67 (0.87%)

17:24
09/18/18
09/18
17:24
09/18/18
17:24
Syndicate
Breaking Syndicate news story on Best Buy »

Best Buy files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DO

Diamond Offshore

$17.86

0.55 (3.18%)

17:22
09/18/18
09/18
17:22
09/18/18
17:22
Initiation
Diamond Offshore initiated at Morgan Stanley »

Diamond Offshore…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSM

TSMC

$43.57

-0.2 (-0.46%)

17:20
09/18/18
09/18
17:20
09/18/18
17:20
Upgrade
TSMC rating change at Morgan Stanley »

TSMC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHD

Cactus

$35.93

1.24 (3.57%)

17:17
09/18/18
09/18
17:17
09/18/18
17:17
Initiation
Cactus initiated at Morgan Stanley »

Cactus initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZTCOY

ZTE Corp.

$0.00

(0.00%)

17:15
09/18/18
09/18
17:15
09/18/18
17:15
Periodicals
Senators seek punishment if ZTE strays from deal, Reuters says »

In a bill, introduced on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKCA

Akcea Therapeutics

$26.58

1.73 (6.96%)

17:15
09/18/18
09/18
17:15
09/18/18
17:15
Syndicate
Breaking Syndicate news story on Akcea Therapeutics »

Akcea Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.